NNVC vs. GOSS, AMLX, OPTN, KPTI, CLRB, CYBN, CRVO, NVCT, ACET, and IMUX
Should you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Gossamer Bio (GOSS), Amylyx Pharmaceuticals (AMLX), OptiNose (OPTN), Karyopharm Therapeutics (KPTI), Cellectar Biosciences (CLRB), Cybin (CYBN), CervoMed (CRVO), Nuvectis Pharma (NVCT), Adicet Bio (ACET), and Immunic (IMUX). These companies are all part of the "pharmaceutical preparations" industry.
Gossamer Bio (NASDAQ:GOSS) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
Gossamer Bio's return on equity of -74.66% beat NanoViricides' return on equity.
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by insiders. Comparatively, 4.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Gossamer Bio received 145 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 65.32% of users gave Gossamer Bio an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
NanoViricides is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
In the previous week, Gossamer Bio and Gossamer Bio both had 1 articles in the media. NanoViricides' average media sentiment score of 1.77 beat Gossamer Bio's score of 0.50 indicating that Gossamer Bio is being referred to more favorably in the media.
Gossamer Bio presently has a consensus price target of $7.65, indicating a potential upside of 1,367.77%. Given NanoViricides' higher possible upside, equities analysts plainly believe Gossamer Bio is more favorable than NanoViricides.
Summary
Gossamer Bio beats NanoViricides on 10 of the 13 factors compared between the two stocks.
Get NanoViricides News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NanoViricides Competitors List
Related Companies and Tools
